300404 博济医药
已收盘 08-19 15:00:00
资讯
新帖
简况
博济医药：临床前研究服务包括药物发现、药学研究、非临床安全性评价（GLP）、药效学研究、药代动力学研究等服务
证券之星 · 08-17 15:45
博济医药：临床前研究服务包括药物发现、药学研究、非临床安全性评价（GLP）、药效学研究、药代动力学研究等服务
8月14日博济医药（300404）龙虎榜数据：机构净买入4939.99万元
证券之星 · 08-14
8月14日博济医药（300404）龙虎榜数据：机构净买入4939.99万元
8月13日博济医药（300404）龙虎榜数据：机构净买入3657.72万元
证券之星 · 08-13
8月13日博济医药（300404）龙虎榜数据：机构净买入3657.72万元
异动快报：博济医药（300404）8月13日9点57分触及涨停板
证券之星 · 08-13
异动快报：博济医药（300404）8月13日9点57分触及涨停板
生物科技板块拉升 博济医药涨超10%
南方财经网 · 08-13
生物科技板块拉升 博济医药涨超10%
博济医药（300404）披露2026年第二次临时股东大会通知，7月15日股价上涨3.12%
证券之星 · 07-15
博济医药（300404）披露2026年第二次临时股东大会通知，7月15日股价上涨3.12%
博济医药（300404）披露高级管理人员辞职公告，6月30日股价下跌2.67%
证券之星 · 06-30
博济医药（300404）披露高级管理人员辞职公告，6月30日股价下跌2.67%
博济医药：6月26日无股东会
证券之星 · 06-25
博济医药：6月26日无股东会
博济医药：公司一直专注主营业务并努力提升公司内在经营价值
证券之星 · 06-25
博济医药：公司一直专注主营业务并努力提升公司内在经营价值
博济医药(300404.SZ)拟定增募资不超4.47亿元 用于中药创新药研发项目等
智通财经 · 06-08
博济医药(300404.SZ)拟定增募资不超4.47亿元 用于中药创新药研发项目等
博济医药（300404）披露部分限制性股票回购注销完成公告，6月1日股价上涨0.3%
证券之星 · 06-01
博济医药（300404）披露部分限制性股票回购注销完成公告，6月1日股价上涨0.3%
博济医药（300404）披露2025年年度股东会决议公告，5月18日股价上涨0.38%
证券之星 · 05-18
博济医药（300404）披露2025年年度股东会决议公告，5月18日股价上涨0.38%
博济医药（300404）披露2023年向特定对象发行股票之保荐总结报告书，5月13日股价下跌0.18%
证券之星 · 05-13
博济医药（300404）披露2023年向特定对象发行股票之保荐总结报告书，5月13日股价下跌0.18%
每周股票复盘：博济医药（300404）一季度订单增74.36%
证券之星 · 05-03
每周股票复盘：博济医药（300404）一季度订单增74.36%
博济医药：4月26日接受机构调研，西部证券、青榕资管等多家机构参与
证券之星 · 04-27
博济医药：4月26日接受机构调研，西部证券、青榕资管等多家机构参与
博济医药（300404）2026年一季报简析：营收净利润同比双双增长，公司应收账款体量较大
证券之星 · 04-26
博济医药（300404）2026年一季报简析：营收净利润同比双双增长，公司应收账款体量较大
博济医药(300404.SZ)发布一季度业绩，归母净利润1646.08万元，增长322.01%
智通财经 · 04-24
博济医药(300404.SZ)发布一季度业绩，归母净利润1646.08万元，增长322.01%
博济医药：公司专注于为医药企业提供药品、医疗器械的全流程“一站式”研发外包服务
证券之星 · 04-08
博济医药：公司专注于为医药企业提供药品、医疗器械的全流程“一站式”研发外包服务
博济医药最新公告：全资子公司获得药物临床试验批准通知书
证券之星 · 04-03
博济医药最新公告：全资子公司获得药物临床试验批准通知书
博济医药（300404）披露已回购股份减持结果暨股份变动公告，3月24日股价上涨4.68%
证券之星 · 03-24
博济医药（300404）披露已回购股份减持结果暨股份变动公告，3月24日股价上涨4.68%
加载更多
公司概况
公司名称：
博济医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2015-04-24
主营业务：
博济医药科技股份有限公司的主营业务是为国内外制药企业及其他研究机构就新药品、医疗器械的研发与生产提供全流程“一站式”CRO服务。公司的主要产品是临床前研究服务、临床研究服务、其他咨询服务、CDMO服务。
发行价格：
12.87
{"stockData":{"symbol":"300404","market":"SZ","secType":"STK","nameCN":"博济医药","latestPrice":15.35,"timestamp":1787122998000,"preClose":16.64,"halted":0,"volume":66113638,"delay":0,"changeRate":-0.0775,"floatShares":286000000,"shares":386000000,"eps":0.1117,"marketStatus":"已收盘","change":-1.29,"latestTime":"08-19 15:00:00","open":16.28,"high":16.47,"low":15.02,"amount":1039000000,"amplitude":0.0871,"askPrice":15.36,"askSize":172,"bidPrice":15.35,"bidSize":631,"shortable":0,"etf":0,"ttmEps":0.1117,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787189400000},"marketStatusCode":5,"adr":0,"adjPreClose":16.64,"symbolType":"stock","openAndCloseTimeList":[[1787103000000,1787110200000],[1787115600000,1787122800000]],"highLimit":18.3,"lowLimit":14.98,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":385748938,"isCdr":false,"pbRate":6.01,"roa":"--","peRate":137.421665,"roe":"1.59%","epsLYR":0.0794,"committee":0.863278,"marketValue":5921000000,"turnoverRate":0.2316,"status":1,"floatMarketCap":4383000000},"requestUrl":"/m/hq/s/300404","defaultTab":"news","newsList":[{"id":"2660348890","title":"博济医药：临床前研究服务包括药物发现、药学研究、非临床安全性评价（GLP）、药效学研究、药代动力学研究等服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2660348890","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660348890?lang=zh_cn&edition=full","pubTime":"2026-08-17 15:45","pubTimestamp":1786952713,"startTime":"0","endTime":"0","summary":"证券之星消息，博济医药(300404)08月17日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵司临床前哪些业务可以平替药明康德？博济医药回复：您好，公司临床前研究服务包括：药物发现、药学研究、非临床安全性评价（GLP）、药效学研究、药代动力学研究等服务。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700015841.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659611036","title":"8月14日博济医药（300404）龙虎榜数据：机构净买入4939.99万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2659611036","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659611036?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:41","pubTimestamp":1786700506,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年8月14日公布的交易公开信息显示，博济医药因日涨幅达到15%的前5只证券，连续三个交易日内，涨幅偏离值累计达到30%的证券登上龙虎榜。此次是近5个交易日内第2次上榜。截至2026年8月14日收盘，博济医药报收于17.34元，上涨20.0%，已连续涨停2天，换手率27.53%，成交量78.61万手，成交额13.2亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入4939.99万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400029888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659715881","title":"8月13日博济医药（300404）龙虎榜数据：机构净买入3657.72万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2659715881","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659715881?lang=zh_cn&edition=full","pubTime":"2026-08-13 17:36","pubTimestamp":1786613806,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年8月13日公布的交易公开信息显示，博济医药因日涨幅达到15%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年8月13日收盘，博济医药报收于14.45元，上涨20.02%，涨停，换手率21.43%，成交量61.19万手，成交额8.23亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入3657.72万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300029150.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659182933","title":"异动快报：博济医药（300404）8月13日9点57分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2659182933","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659182933?lang=zh_cn&edition=full","pubTime":"2026-08-13 10:05","pubTimestamp":1786586732,"startTime":"0","endTime":"0","summary":"证券之星8月13日盘中消息，9点57分博济医药（300404）触及涨停板。其所属行业医疗服务目前上涨。领涨股为博济医药。该股为创新药，干细胞，减肥药概念热股，当日创新药概念上涨2.15%，干细胞概念上涨2.11%，减肥药概念上涨2.0%。8月12日的资金流向数据方面，主力资金净流出2871.15万元，占总成交额4.77%，游资资金净流出2732.44万元，占总成交额4.54%，散户资金净流入5603.59万元，占总成交额9.31%。近5日资金流向一览见下表：博济医药主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300010238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659689182","title":"生物科技板块拉升 博济医药涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659689182","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659689182?lang=zh_cn&edition=full","pubTime":"2026-08-13 09:49","pubTimestamp":1786585772,"startTime":"0","endTime":"0","summary":"生物科技板块拉升 博济医药涨超10%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608133840135180.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608133840135180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ARTY","BK4585","BK4588","BK0216","XLK","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651469721","title":"博济医药（300404）披露2026年第二次临时股东大会通知，7月15日股价上涨3.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651469721","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651469721?lang=zh_cn&edition=full","pubTime":"2026-07-15 22:11","pubTimestamp":1784124673,"startTime":"0","endTime":"0","summary":"截至2026年7月15日收盘，博济医药报收于10.25元，较前一交易日上涨3.12%，最新总市值为39.54亿元。该股当日开盘9.8元，最高10.7元，最低9.75元，成交额达4.18亿元，换手率为14.17%。近日，博济医药科技股份有限公司披露《关于召开2026年第二次临时股东会的通知》。公告显示，公司将于2026年7月31日召开2026年第二次临时股东会，会议采取现场表决与网络投票相结合方式，股权登记日为2026年7月27日。中小投资者表决将单独计票并披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500044715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647557827","title":"博济医药（300404）披露高级管理人员辞职公告，6月30日股价下跌2.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647557827","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647557827?lang=zh_cn&edition=full","pubTime":"2026-06-30 22:43","pubTimestamp":1782830595,"startTime":"0","endTime":"0","summary":"博济医药科技股份有限公司近日披露《关于高级管理人员辞职的公告》。公告显示，公司董事会于近日收到副总经理左联女士的书面辞职报告，因个人原因，左联女士申请辞去公司副总经理职务，辞职后不再担任公司其他职务。左联女士的离任自2026年6月30日起生效，原定任期至2026年8月2日。截至公告日，左联女士持有公司股票98,000股，无未履行承诺，离任后将按规定继续遵守股份减持相关法律法规。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000047395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646875982","title":"博济医药：6月26日无股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2646875982","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646875982?lang=zh_cn&edition=full","pubTime":"2026-06-25 17:00","pubTimestamp":1782378039,"startTime":"0","endTime":"0","summary":"证券之星消息，博济医药(300404)06月25日在投资者关系平台上答复投资者关心的问题。投资者提问：6.26号有会议吗？博济医药回复：您好，6月26日无股东会，公司于2026年6月24日召开了第一次临时股东会，详细情况可查阅公司6月25日在巨潮资讯网（www.cninfo.com.cn）上披露的相关公告。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500030392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646875653","title":"博济医药：公司一直专注主营业务并努力提升公司内在经营价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2646875653","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646875653?lang=zh_cn&edition=full","pubTime":"2026-06-25 16:57","pubTimestamp":1782377835,"startTime":"0","endTime":"0","summary":"3、本次向特定对象发行股票方案尚需深交所审核通过且经中国证监会同意注册后方可实施，最终发行情况根据发行当日投资者认购情况决定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500030282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641879934","title":"博济医药(300404.SZ)拟定增募资不超4.47亿元 用于中药创新药研发项目等","url":"https://stock-news.laohu8.com/highlight/detail?id=2641879934","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641879934?lang=zh_cn&edition=full","pubTime":"2026-06-08 21:46","pubTimestamp":1780926415,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博济医药(300404.SZ)发布公告，公司拟向不超过35名符合中国证监会规定条件的特定投资者发行A股股票，发行募集资金总额不超过4.47亿元，扣除发行费用后拟将全部用于：药物评价中心扩建升级项目、中药创新药研发项目、医药研发大数据智能一体化平台项目、SMO中心建设项目、补充流动资金。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK1161","BK0216","BK1574","06978","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640950611","title":"博济医药（300404）披露部分限制性股票回购注销完成公告，6月1日股价上涨0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640950611","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640950611?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:24","pubTimestamp":1780323865,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，博济医药报收于10.0元，较前一交易日上涨0.3%，最新总市值为38.59亿元。近日，博济医药科技股份有限公司发布《关于部分限制性股票回购注销完成的公告》。本次回购注销完成后，公司总股本由385,975,208股减少至385,745,208股，公司股权分布仍具备上市条件，不影响公司管理团队稳定性及正常经营。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100041098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636506074","title":"博济医药（300404）披露2025年年度股东会决议公告，5月18日股价上涨0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636506074","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636506074?lang=zh_cn&edition=full","pubTime":"2026-05-18 22:28","pubTimestamp":1779114503,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，博济医药报收于10.7元，较前一交易日上涨0.38%，最新总市值为41.29亿元。该股当日开盘10.59元，最高10.75元，最低10.45元，成交额达1.07亿元，换手率为3.52%。近日，博济医药科技股份有限公司发布《2025年年度股东会决议公告》。会议表决程序合法，所有议案均获通过。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800037657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635200447","title":"博济医药（300404）披露2023年向特定对象发行股票之保荐总结报告书，5月13日股价下跌0.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635200447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635200447?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:58","pubTimestamp":1778666339,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，博济医药报收于10.8元，较前一交易日下跌0.18%，最新总市值为41.67亿元。博济医药于近日披露《广发证券股份有限公司关于公司2023年向特定对象发行股票之保荐总结报告书》。公告显示，博济医药科技股份有限公司2023年向特定对象发行A股股票11,759,601股，发行价格7.03元/股，募集资金净额78,647,586.29元，于2023年12月8日在深圳证券交易所上市。广发证券作为保荐人，持续督导期至2025年12月31日届满，期间公司未发生重大事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300033369.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632260896","title":"每周股票复盘：博济医药（300404）一季度订单增74.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632260896","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2632260896?lang=zh_cn&edition=full","pubTime":"2026-05-03 08:23","pubTimestamp":1777767791,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，博济医药报收于10.74元，较上周的10.19元上涨5.4%。本周，博济医药4月28日盘中最高价报11.16元。4月29日盘中最低价报10.43元。AI布局方面，引入第三方AI工具优化患者招募、方案设计、风险监查与数据管理，并组建AI团队自主开发，推动临床研究数字化与智能化转型。化药2.2类“氟康唑滴耳液”2025年取得IND，近期已对外转让。2025年及2026年第一季度，公司三费费用率均同比下降，随营收规模扩大，费用率预计进一步下降。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300002080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630235501","title":"博济医药：4月26日接受机构调研，西部证券、青榕资管等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2630235501","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630235501?lang=zh_cn&edition=full","pubTime":"2026-04-27 11:01","pubTimestamp":1777258903,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年4月27日博济医药发布公告称公司于2026年4月26日接受机构调研，西部证券、青榕资管、万汇投资、进门财经、光大医药、申万宏源、国信证券、中泰证券、国泰海通、兴业证券、尚诚资管、中金公司、中信期货参与。博济医药2026年一季报显示，一季度公司主营收入2.2亿元，同比上升58.54%；归母净利润1646.08万元，同比上升322.01%；扣非净利润1370.84万元，同比上升707.37%；负债率34.06%，投资收益44.32万元，财务费用21.63万元，毛利率28.45%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700015472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0276","BK0028","BK0216","BK0183","BK0188","002673"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630280723","title":"博济医药（300404）2026年一季报简析：营收净利润同比双双增长，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2630280723","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630280723?lang=zh_cn&edition=full","pubTime":"2026-04-26 06:27","pubTimestamp":1777156057,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期博济医药发布2026年一季报。截至本报告期末，公司营业总收入2.2亿元，同比上升58.54%，归母净利润1646.08万元，同比上升322.01%。本报告期博济医药公司应收账款体量较大，当期应收账款占最新年报归母净利润比达675.58%。本次财报公布的各项数据指标表现尚佳。去年的净利率为3.79%，算上全部成本后，公司产品或服务的附加值不高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600003726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629892823","title":"博济医药(300404.SZ)发布一季度业绩，归母净利润1646.08万元，增长322.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629892823","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2629892823?lang=zh_cn&edition=full","pubTime":"2026-04-24 23:03","pubTimestamp":1777043014,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博济医药(300404.SZ)发布2026年第一季度报告，该公司营业收入为2.2亿元，同比增长58.54%。归属于上市公司股东的净利润为1646.08万元，同比增长322.01%。归属于上市公司股东的扣除非经常性损益的净利润为1370.84万元，同比增长707.37%。基本每股收益为0.043元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"博济医药(300404.SZ)发布一季度业绩，归母净利润1646.08万元，增长322.01%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625999270","title":"博济医药：公司专注于为医药企业提供药品、医疗器械的全流程“一站式”研发外包服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2625999270","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2625999270?lang=zh_cn&edition=full","pubTime":"2026-04-08 11:34","pubTimestamp":1775619242,"startTime":"0","endTime":"0","summary":"证券之星消息，博济医药04月07日在投资者关系平台上答复投资者关心的问题。博济医药回复：您好，目前公司没有与药石科技合作，公司专注于为医药企业提供药品、医疗器械的全流程“一站式”研发外包服务，包括：临床前研究服务、临床研究服务、其他咨询服务以及CDMO服务，其中临床研究服务为公司最主要的业务板块，占公司整体营业收入80%以上。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040800014274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","09996","159883","BK1100","BK1583","BK1222","09997","BK1574","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624151657","title":"博济医药最新公告：全资子公司获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2624151657","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2624151657?lang=zh_cn&edition=full","pubTime":"2026-04-03 20:20","pubTimestamp":1775218803,"startTime":"0","endTime":"0","summary":"博济医药(300404.SZ)公告称，公司全资子公司杏林中医药科技(广州)有限公司申报的“丹元糖痹软膏”获得国家药品监督管理局核准签发的《药物临床试验批准通知书》。该药品为中药1.1类创新药，适应症为糖尿病周围神经病变，具有活血行气、通络止痛功效。本次获批是新药研发的阶段性成果，不会对公司经营业绩产生重大影响。鉴于药品研发周期长、环节多，临床试验进度及结果、未来市场竞争等存在不确定性，敬请投资者注意投资风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300040171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621095440","title":"博济医药（300404）披露已回购股份减持结果暨股份变动公告，3月24日股价上涨4.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095440","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2621095440?lang=zh_cn&edition=full","pubTime":"2026-03-24 22:47","pubTimestamp":1774363634,"startTime":"0","endTime":"0","summary":"截至2026年3月24日收盘，博济医药报收于9.4元，较前一交易日上涨4.68%，最新总市值为36.27亿元。博济医药科技股份有限公司近日披露《关于已回购股份减持结果暨股份变动公告》。公告显示，公司于2026年3月24日完成回购股份的集中竞价减持，累计减持2,667,000股，占总股本0.69%，减持所得资金总额25,741,470.00元，成交均价9.65元/股。减持后回购专用账户余额为0，公司总股本不变，未导致控制权及股权结构变动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400040387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787146010635,"stockEarnings":[{"period":"1week","weight":0.4114},{"period":"1month","weight":0.7102},{"period":"3month","weight":0.5604},{"period":"6month","weight":0.5781},{"period":"1year","weight":0.5205},{"period":"ytd","weight":0.7862}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":0.0601},{"period":"3month","weight":-0.0413},{"period":"6month","weight":-0.0225},{"period":"1year","weight":0.0704},{"period":"ytd","weight":0.0054}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"博济医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"31226人(较上一季度增加15.23%)","perCapita":"9143股","listingDate":"2015-04-24","address":"广东省广州市黄埔区科学城南翔一路62号(二、三、四、五)栋","registeredCapital":"38574万元","survey":" 博济医药科技股份有限公司的主营业务是为国内外制药企业及其他研究机构就新药品、医疗器械的研发与生产提供全流程“一站式”CRO服务。公司的主要产品是临床前研究服务、临床研究服务、其他咨询服务、CDMO服务。","listedPrice":12.87},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博济医药(300404)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博济医药(300404)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博济医药,300404,博济医药股票,博济医药股票老虎,博济医药股票老虎国际,博济医药行情,博济医药股票行情,博济医药股价,博济医药股市,博济医药股票价格,博济医药股票交易,博济医药股票购买,博济医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博济医药(300404)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博济医药(300404)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}